Dai Tianxing, Deng Mingbin, Ye Linsen, Liu Rongqiang, Lin Guozhen, Chen Xiaolong, Li Hua, Liu Wei, Yang Yang, Chen Guihua, Wang Guoying
Department of Hepatic Surgery and Liver Transplant Program, The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630, China.
Organ Transplantation Institute of Sun Yat-Sen University Guangzhou 510630, China.
Am J Transl Res. 2020 Jun 15;12(6):2984-2997. eCollection 2020.
The gamma-glutamyl transpeptidase to platelet ratio (GPR) has been reported as a non-invasive parameter for evaluating hepatic fibrosis and cirrhosis. However, only a few of studies investigated the relationship between GPR and liver cancer. Here, we sought to clarify the prognostic value of GPR as well as its combination with fibrinogen in patients with HBV-related hepatocellular carcinoma (HCC). We performed a retrospective study using data collected from 302 HCC patients, and evaluated the association between GPR, fibrinogen and clinicopathological characteristics using the chi-square test. Additionally, we assessed disease-free survival (DFS) and overall survival (OS) using the Kaplan-Meier method and log-rank test, then performed univariate and multivariate COX analyses to identify the prognostic factors. The prognostic performance of combined GPR and fibrinogen was evaluated by the receiver operating characteristic curve analysis. Results showed that GPR was associated with gender, history of smoking and drinking, cirrhosis, antiviral treatments, tumor number, and Child-Pugh grade. Univariate analysis revealed a significant correlation between tumor diameter, vascular invasion, BCLC stage, alpha-fetal protein, GPR, fibrinogen, and NLR with both DFS and OS in HCC patients. Only GPR and fibrinogen were found to be independently associated with both DFS and OS according to multivariate analysis. Furthermore, predictive capacity was enhanced by combining GPR with fibrinogen owing to a larger area under the curve than other indexes or models. Overall, preoperative GPR could be an effective non-invasive predictor for prognosis of HBV-related HCC patients, and a combination of GPR and fibrinogen improved the prognostic performance.
γ-谷氨酰转肽酶与血小板比值(GPR)已被报道为评估肝纤维化和肝硬化的非侵入性参数。然而,仅有少数研究探讨了GPR与肝癌之间的关系。在此,我们旨在阐明GPR及其与纤维蛋白原联合应用对乙肝相关肝细胞癌(HCC)患者的预后价值。我们进行了一项回顾性研究,使用从302例HCC患者收集的数据,并采用卡方检验评估GPR、纤维蛋白原与临床病理特征之间的关联。此外,我们使用Kaplan-Meier方法和对数秩检验评估无病生存期(DFS)和总生存期(OS),然后进行单因素和多因素COX分析以确定预后因素。通过受试者工作特征曲线分析评估联合GPR和纤维蛋白原的预后性能。结果显示,GPR与性别、吸烟和饮酒史、肝硬化、抗病毒治疗、肿瘤数量及Child-Pugh分级相关。单因素分析显示,肿瘤直径、血管侵犯、BCLC分期、甲胎蛋白、GPR、纤维蛋白原和中性粒细胞与淋巴细胞比值(NLR)与HCC患者的DFS和OS均显著相关。多因素分析显示,仅GPR和纤维蛋白原与DFS和OS均独立相关。此外,由于联合GPR和纤维蛋白原的曲线下面积大于其他指标或模型,其预测能力得到增强。总体而言,术前GPR可能是乙肝相关HCC患者预后的有效非侵入性预测指标,GPR与纤维蛋白原联合应用可改善预后性能。